• Like
FDA's advice on asset bee pollen
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

FDA's advice on asset bee pollen


On 12th May 2014, the Food and Drug Administration (FDA) is advising consumers not to purchase or use “Asset Bee Pollen” and it is found to contain Sibutramine during FDA laboratory analysis.

On 12th May 2014, the Food and Drug Administration (FDA) is advising consumers not to purchase or use “Asset Bee Pollen” and it is found to contain Sibutramine during FDA laboratory analysis.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On SlideShare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. FDA’s advice on “Asset Bee Pollen” Dr. P.NaiNa MohaMeD PharMacologist
  • 2. Introduction On 12th May 2014, the Food and Drug Administration (FDA) is advising consumers not to purchase or use “Asset Bee Pollen”. “Asset Bee Pollen” is promoted and sold for weight loss and sold on various websites, including www.assetcapsules4u.com, and in some retail stores.  FDA laboratory analysis confirmed that “Asset Bee Pollen” contains Sibutramine. Sibutramine is a controlled substance and it was removed from the market in October 2010 for safety reasons. 
  • 3. Possible Mechanism of action
  • 4. Risks of Asset Bee Pollen
  • 5. Contraindications of Asset Bee Pollen (Sibutramine)  “Asset Bee Pollen” should not be used by the patient who has..  History of cerebrovascular disease (stroke or transient ischemic attack)  History of congestive heart failure  History of coronary artery disease (eg, angina, myocardial infarction)  History of cardiac arrhythmias  History of peripheral arterial occlusive disease  Uncontrolled hypertension.  Major eating disorders, major (eg, anorexia nervosa or bulimia nervosa)  Concomitant use with MAOIs  Concomitant use with other centrally acting weight loss drugs
  • 6. Serious Drug Interactions
  • 7. Interaction with Antidepressants
  • 8. Interaction with NSAIDs
  • 9. Interaction with Decongestants
  • 10. Interaction with CYP3A4 Inhibitors
  • 11. FDA Warnings • FDA warns the Consumers should stop using this product immediately and throw it away.  • FDA advises the Consumers who have experienced any negative side effects should consult a health care professional as soon as possible.  • FDA announces to the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals.  These products are typically promoted for sexual enhancement, weight loss, and body building, and are often represented as being “all natural.”  • FDA claims that they are unable to test and identify all products marketed as dietary supplements on the market that have potentially harmful hidden ingredients.  • FDA advises the Consumers to exercise caution before purchasing any product in the above categories. 
  • 12. FDA Warnings  FDA has requested market withdrawal after reviewing data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT).  SCOUT is part of a postmarket requirement to look at cardiovascular safety of sibutramine after the European approval of the drug.   The trial demonstrated a 16 percent increase in the risk of serious heart events, including non-fatal heart attack, non-fatal stroke, the need to be resuscitated once the heart stopped, and death, in a group of patients given sibutramine compared with another given placebo.  There was a small difference in weight loss between the placebo group and the group that received sibutramine.  RECOMMENDATION: Physicians are advised to stop prescribing Sibutramine (Meridia) to their patients, and patients should stop taking this medication.  Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedica
  • 13. References http:// www.fda.gov/Drugs/ResourcesForYou/Consumer s/BuyingUsingMedicineSafely/MedicationHealthFr aud/ucm396796.htm? source=govdelivery&utm_medium=email&utm_s ource=govdelivery http://www.micromedexsolutions.com CURRENT Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy, 2e Norton J. Greenberger, Richard S. Blumberg, Robert Burakoff Clinician's Pocket Reference, 11e Leonard G. Gomella, Steven A. Haist Harrison's Online Featuring the complete contents of Harrison's Principles of Internal Medicine, 18e Basic & Clinical Pharmacology, 12e Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor
  • 14. References  http://www.fda.gov/safety/medwatch/safetyinformati on/safetyalertsforhumanmedicalproducts/ucm22883 0.htm  http://www.tga.gov.au/safety/alerts-medicine- sibutramine-101008.htm  http://www.medsafe.govt.nz/hot/media/2010/Sibutra mineOct2010.asp  http://www.bmj.com/content/340/bmj.c824